**Supplemental Table 1. The primer sequences**

|  |  |
| --- | --- |
| *IL-6* | F:5′- GAG GAT ACC CCC AAC AGA CC-3′  R:5′-AAG TGC ATC ATC GTT GTT CAT ACA′-3 |
| *TNF-α* | F:5′- CAT CTT CTC AAA ATT CGA GTG ACA A -3′ |
| R:5′- TGG GAG TAG ACA AGG TAC AAC CC-3′ |
| *IL-1β* | F:5′- GCA ACT GTT CCT GAA CTC AAC T -3′ |
|  | R:5′- ATC TTT TGG GGT CCG TCA ACT -3′ |
| *TGF-β* | F:5′- CTC CCG TGG CTT CTA GTG C-3′ |
|  | R:5′- GCC TTA GTT TGG ACA GGA TCT G-3′ |
| *MCP-1* | F:5′- CTT CTG GGC CTG CTG TTC A-3′ |
|  | R:5′- CCA GCC TAC TCA TTG GGA TCA-3′ |
| *INOS* | F:5′- GTT CTC AGC CCA ACA ATA CAA GA-3′ |
|  | R:5′- GTG GAC GGG TCG ATG TCA C-3′ |
| *IL-10* | F:5′- GGTTGCCAAGCCTTATCGGA-3′ |
|  | R:5′- ACCTGCTCCACTGCCTTGCT-3′ |
| *COLα-1* | F:5′- GCT CCT CTT AGG GGC CAC T-3′ |
|  | R:5′- CCA CGT CTC ACC ATT GGG G-3′ |
| *COL-3* | F:5′- CCT GGC TCA AAT GGC TCA C-3′ |
|  | R:5′- CAG GAC TGC CGT TAT TCC CG-3′ |
| *MMP-13* | F:5′- CTT CTT CTT GTT GAG CTG GAC TC-3′ |
|  | R:5′- CTG TGG AGG TCA CTG TAG ACT-3′ |
| *TIMP-1* | F:5′-GCA ACT CGG ACC TGG TCA TAA-3′ |
|  | R:5′- CGG CCC GTG ATG AGA AAC T-3′ |
| *β-actin* | F:5′-CAG CTT CTT TGC AGC TCC TT-3′ |
|  | R:5′-CAC GAT GGA GGG GAA TAC AG-3′ |

**Supplemental Table 2. Body weight after percutaneous administration CCEs in rats**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Dose （mg/kg） | Gender | Number | Body weight（g**,±*s***） | | | | |
| D1 | | D8 | | D15 |
| 2000 | ♀ | 5 | 205.22±7.04 | 234.54±7.04 | | 265.37±6.66 | |
| 2000 | ♂ | 5 | 325.97±13.40 | 352.05±13.40 | | 381.13±13.28 | |

**Supplemental Table 3. Clinical observation of individual rat after CCE treatment**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| DOSE （mg/kg） | Gender | ID number | General clinical observation | | | | | | | | | | | | | | | |
| 30 min | 4 h | D2 | D3 | D4 | D5 | D6 | D7 | D8 | D9 | D10 | D11 | D12 | D13 | D14 | D15 |
| 550 | ♀ | 1 | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N |
| 2000 | 2 | N | R | D | / | / | / | / | / | / | / | / | / | / | / | / | / |
| 550 | 3 | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N |
| 2000 | 4 | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N |
| 2000 | 5 | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N |
| 2000 | 6 | N | R | D | / | / | / | / | / | / | / | / | / | / | / | / | / |
| 550 | 7 | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N |
| 2000 | 8 | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N |
| 2000 | 9 | N | R | D | / | / | / | / | / | / | / | / | / | / | / | / | / |
| 550 | 10 | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N |
| 2000 | 11 | N | R | R | R | D | / | / | / | / | / | / | / | / | / | / | / |
| 2000 | 12 | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N |
| 2000 | 13 | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N |

Note: R = reduced activity; N = no abnormalities; D = death.

**Supplemental Table 4. Body weight after oral administration CCEs in rats**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Dose （mg/kg） | Gender | Number | Body Weight（g**, ±*s***） | | |
| D1 | D8 | D15 |
| 550 | ♀ | 4 | 190.09 ± 6.93 | 214.29 ± 6.88 | 234.13 ± 10.62 |
| 2000 | ♀ | 9 | 195.57 ± 3.08 | 221.49 ± 7.73 | 240.10 ± 8.86 |

**Supplemental Table 5. Colony count result of Ames test**

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Group | | Dose  (mg/D） | Reverse Mutation Colony（C/D，±s，N=3） | | | | | | | | | |
| TA97 | | TA98 | | TA100 | | TA102 | | TA1535 | |
| －S9 | ＋S9 | －S9 | ＋S9 | －S9 | ＋S9 | －S9 | ＋S9 | －S9 | ＋S9 |
| Negative control | | water | 131±28 | 133±4 | 15±8 | 25±3 | 149±16 | 116±19 | 458±12 | 435±27 | 13±3 | 12±3 |
| CCEs | | 5 | 110±38 | 123±46 | 19±8 | 21±2 | 128±4 | 134±27 | 371±13 | 456±12 | 12±2 | 8±4 |
| CCEs | | 1 | 97±12 | 104±36 | 15±2 | 18±3 | 151±10 | 120±13 | 367±28 | 395±24 | 12±3 | 12±2 |
| CCEs | | 0.2 | 96±16 | 111±16 | 12±3 | 24±4 | 138±29 | 121±4 | 377±5 | 417±39 | 13±1 | 12±2 |
| CCEs | | 0.04 | 121±10 | 94±9 | 18±4 | 28±3 | 158±16 | 140±28 | 402±40 | 417±26 | 13±2 | 12±1 |
| CCEs | | 0.008 | 130±12 | 129±13 | 20±8 | 23±2 | 162±33 | 134±17 | 416±42 | 381±19 | 13±2 | 14±4 |
| Positive control | ICR191 | 0.002 | 1079±75\*\* | / | */* | / | / | / | / | / | / | / |
| 2-Nitrofluorene | 0.01 | */* | */* | 1117±231\* | */* | */* | */* | */* | */* | */* | */* |
| NaN3 | 0.002 | */* | */* | */* | */* | 860±63\*\* | / | */* | */* | 1128±320\*\* | / |
| Mitomycin C | 0.002 | */* | */* | */* | */* | */* | */* | 1573±94\*\* | / | */* | */* |
| 2-Aminofluorene | 0.01 | */* | 501±49\*\* | */* | 1577±534\* | / | 500±4\*\* | / | 1671±127\*\* | */* | */* |
| cyclophosphamide | 0.2 | */* | */* | */* | */* | */* | */* | */* | */* | / | 202±14\*\* |

Note：\*，Indicates a difference in the negative control（*P*<0.05）；\*\*，Indicates a significant difference in the negative control group（*P*<0.01）。